Medtronic Spinoff MiniMed Stumbles in Nasdaq Debut Amid Market Volatility
MiniMed's Nasdaq debut fell short of expectations as shares opened 4.8% below the IPO price, raising $560 million at a $5.35 billion valuation. The medical device spinoff from Medtronic faced headwinds from broader market turbulence, with the VIX hitting a four-month high following disappointing jobs data.
The offering priced substantially below its marketed range of $25-$28 per share, selling 28 million shares at $20 each. Medtronic retains 90% ownership post-IPO, leaving minimal public float. Analysts had questioned the initial valuation targets, and the weak debut validates those concerns.
New listings continue to face challenging conditions as investors grapple with macroeconomic uncertainty and shifting sector dynamics. The tepid reception for MiniMed's IPO underscores the current risk-off sentiment in equity markets.
